Tacabrutideg and the Future of Targeted Therapies: Key Insights for Oncology Healthcare Professionals

BGB-16673 (Tacabrutideg) is a novel, investigational Bruton’s tyrosine kinase (BTK) protein degrader being studied in patients with B-cell malignancies, including those whose diseases have relapsed or are refractory following treatment with covalent BTK inhibitors. Early-phase studies are assessing its safety, efficacy, and potential treatment uses in patients with B-cell malignancies.